




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

February 11, 2005

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
February 11, 2005	
Date	Steven L. Highlander

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/791,219 entitled "INTRACELLULAR SIGNALING PATHWAYS IN DIABETIC SUBJECTS" – Lois Weisman*
Our reference: IOWA:048US
UIRF Ref. 03039


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references B1 and C1-C62.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:048US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/kvp
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Lois Weisman

Serial No.: 10/791,219

Filed: March 2, 2004

For: INTRACELLULAR SIGNALING
PATHWAYS IN DIABETIC SUBJECTS

Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: IOWA:048US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 11, 2005

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/IOWA:048US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 11, 2005

Form PTO-1449 (modified)

FEB 14 2005

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

IOWA:048US

Serial No.

10/791,219

Applicant

Lois Weisman

Filing Date:

March 2, 2004

Group:

1653

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 02/092626	11/21/02	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bauer <i>et al.</i> , "Multiprotein complexes from eukaryotes," Database OPOP Online, XP002299766, Database accession No. AX595285, 2002.
	C2	Bonangelino <i>et al.</i> , "Vac7p, a novel vacuolar protein, is required for normal vacuole inheritance and morphology," <i>Mol. Cell Biol.</i> , 17(12):6847-6858, 1997.
	C3	Bonangelino <i>et al.</i> , "Osmotic stress-induced increase of phosphatidylinositol 3,5-bisphosphate requires Vac14p, an activator of the lipid kinase Fab1p, <i>J. Cell Biol.</i> , 156(6):1015-1028, 2002.
	C4	Bryant <i>et al.</i> , "Retrograde traffic out of the yeast vacuole to the TGN occurs via the prevacuolar/endosomal compartment," <i>J. Cell Biol.</i> , 142(3):651-653, 1998.
	C5	Dove <i>et al.</i> , "Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis," <i>Nature</i> , 390(6656):187-192, 1997.
	C6	Dove <i>et al.</i> , "Vac14 controls PtdIns(3,5)P(2) synthesis and Fab1-dependent protein trafficking to the multivesicular body," <i>Curr. Biol.</i> , 12(11):885-893, 2002.
	C7	Foti <i>et al.</i> , "Sac1 lipid phosphatase and Stt4 phosphatidylinositol 4-kinase regulate a pool of phosphatidylinositol 4-phosphate that functions in the control of the actin cytoskeleton and vacuole morphology," <i>Mol. Biology of the Cell</i> , 12(8):2396-2411, 2001.
	C8	Gary <i>et al.</i> , "Fab1p is essential for ptdins(3)P 5-kinase activity and the maintenance of vacuolar size and membrane homeostasis," <i>J. Cell Biol.</i> , 143(1):65-79, 1998.

25414660.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:048US	Serial No. 10/791,219
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lois Weisman	
		Filing Date: March 2, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Gary <i>et al.</i> , "Regulation of Fab1 phosphatidylinositol 3-phosphate 5-kinase pathway by Vac7 protein and fig4, a polyphosphoinositide phosphatase family member," <i>Mol. Biol. Cell</i> , 13(4):1238-1251, 2002.
	C10	GenBank Accession Number AA036005.
	C11	GenBank Accession Number AA050423.
	C12	GenBank Accession Number AA058300.
	C13	GenBank Accession Number AA273168.
	C14	GenBank Accession Number AA497446.
	C15	GenBank Accession Number AA670618.
	C16	GenBank Accession Number AAD12702.
	C17	GenBank Accession Number AAF54829.
	C18	GenBank Accession Number AL527155.
	C19	GenBank Accession Number AL535971.
	C20	GenBank Accession Number AL555680.
	C21	GenBank Accession Number AL556062.
	C22	GenBank Accession Number BE409891.
	C23	GenBank Accession Number BE573148.
	C24	GenBank Accession Number BE696780.
	C25	GenBank Accession Number BE728471.
	C26	GenBank Accession Number BE893810.
	C27	GenBank Accession Number BE901196.
	C28	GenBank Accession Number BE937614.
	C29	GenBank Accession Number BF023070.
	C30	GenBank Accession Number BF081182.

25414660.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:048US	Serial No. 10/791,219
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lois Weisman	
		Filing Date: March 2, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	GenBank Accession Number BF091052.
	C32	GenBank Accession Number BF162275.
	C33	GenBank Accession Number BF237130.
	C34	GenBank Accession Number BF325708.
	C35	GenBank Accession Number BF720417.
	C36	GenBank Accession Number BG079707.
	C37	GenBank Accession Number BG107035.
	C38	GenBank Accession Number CAB00043.
	C39	GenBank Accession Number CAB08779.
	C40	GenBank Accession Number W09660.
	C41	Guo <i>et al.</i> , "On the relationship of OSW-1 to the cephalostatins," <i>Bioorg. Med. Chem. Lett.</i> , 9(3):419-424, 1999.
	C42	Guo <i>et al.</i> , "SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases," <i>J. Biol. Chem.</i> , 274:12990-12995, 1999.
	C43	Hughes <i>et al.</i> , "SAC1 encodes a regulated lipid phosphoinositide phosphatase, defects in which can be suppressed by the homologous Inp52p and Inp53p phosphatases," <i>J. Biol. Chem.</i> , 275(2):801-808, 2000.
	C44	Ikonomov <i>et al.</i> , <i>J. Biol. Chem.</i> , "Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of PtdIns 3,5-P2 production for endomembrane integrity," 277(11):9206-9211, 2002.
	C45	Ikonomov <i>et al.</i> , "Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve," <i>J. Biol. Chem.</i> , 276(28):26141-26147, 2002.
	C46	Itoh <i>et al.</i> , "Autophosphorylation of type I phosphatidylinositol phosphate kinase regulates its lipid kinase activity," <i>J. Biol. Chem.</i> , 275(25):19389-19394, 2000.
	C47	Jones <i>et al.</i> , "The identification of phosphatidylinositol 3,5-bisphosphate in T-lymphocytes and its regulation by interleukin-2," <i>J. Biol. Chem.</i> , 274(26):18407-18413, 1999.

25414660.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:048US	Serial No. 10/791,219
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lois Weisman	
		Filing Date: March 2, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C48	Johnston <i>et al.</i> , "YL86-yeast," <i>Nature</i> , abstract, 387:87-90, 2001.
	C49	Maehama and Dixon, "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate," <i>J. Biol. Chem.</i> , 273(22):13375-13378, 1998.
	C50	McEwen <i>et al.</i> , 'Complementation analysis in PtdInsP kinase-deficient yeast mutants demonstrates that <i>Schizosaccharomyces pombe</i> and murine Fab1p homologues are phosphatidylinositol 3-phosphate 5-kinases," <i>J. Biol. Chem.</i> , 274(48):33905-33912, 1999.
	C51	Ota <i>et al.</i> , "FYV1_HUMAN," Accession Number Q9Y2I7, October 16, 2001.
	C52	Sbrissa <i>et al.</i> , "PIKfyve, a mammalian ortholog of yeast Fab1p lipid kinase, synthesizes 5-phosphoinositides. Effect of insulin," <i>J. Biol. Chem.</i> , 274(31):21589-21597, 1999.
	C53	Sbrissa <i>et al.</i> , "PIKfyve lipid kinase is a protein kinase: downregulation of 5'-phosphoinositide product formation by autophosphorylation," <i>Biochemistry</i> , 39(51):15980-15989, 2000.
	C54	Sbrissa <i>et al.</i> , "Phosphatidylinositol 3-phosphate-interacting domains in PIKfyve," <i>J. Biol. Chem.</i> , 277(8):6073-6079, 2002.
	C55	Shisheva <i>et al.</i> , "Cloning, characterization, and expression of a novel Zn ²⁺ -binding FYVE finger-containing phosphoinositide kinase in insulin-sensitive cells," <i>Mol. Cell Biol.</i> , 19(1):623-634, 1999.
	C56	Shisheva <i>et al.</i> , "Localization and insulin-regulated relocation of phosphoinositide 5-kinase PIKfyve in 3T3-L1 adip," <i>J. Biol. Chem.</i> , 276(15):11859-11869, 2001.
	C57	Srinivasan <i>et al.</i> , "Disruption of three phosphatidylinositol-polyphosphate 5-phosphatase genes from <i>Saccharomyces cerevisiae</i> results in pleiotropic abnormalities of vacuole morphology, cell shape, and osmohomeostasis," <i>Eur. J. Cell Biol.</i> , 74(4):350-360, 1997.
	C58	Stolz <i>et al.</i> , "INP51, a yeast inositol polyphosphate 5-phosphatase required for phosphatidylinositol 4,5-bisphosphate homeostasis and whose absence confers a cold-resistant phenotype," <i>J. Biol. Chem.</i> , 273(19):11852-11861, 1998.
	C59	Stolz <i>et al.</i> , "Identification and characterization of an essential family of inositol polyphosphate 5-phosphatases (INP51, INP52 and INP53 gene products) in the yeast <i>Saccharomyces cerevisiae</i> ," <i>Genetics</i> , 148(4):1715-1729, 1998.

25414660.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. IOWA:048US	Serial No. 10/791,219
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lois Weisman	
		Filing Date: March 2, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C60	Taylor <i>et al.</i> , "Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate," <i>Proc. Natl. Acad. Sci., USA</i> , 97(16):8910-8915, 2000.
	C61	Vancurova <i>et al.</i> , "Regulation of phosphatidylinositol 4-phosphate 5-kinase from <i>Schizosaccharomyces pombe</i> by casein kinase I," <i>J. Biol. Chem.</i> , 274(2):1147-1155, 1999.
	C62	Whiteford <i>et al.</i> , "Phosphatidylinositol 3,5-bisphosphate defines a novel PI 3-kinase pathway in resting mouse fibroblasts," <i>Biochem. J.</i> , 323(pt3):597-601, 1997.

25414660.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.